The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML).
Alfonso Quintás-cardama, MD
Advertisement
Articles by Alfonso Quintás-cardama, MD
Advertisement
Latest Updated Articles
- Management of Patients With Resistant or Refractory Chronic Myelogenous Leukemia
Published: April 15th 2008 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
3
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
4
Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC
5
